Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01605825 · ClinicalTrials.gov registry record · Phase 2

A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke

A Phase 2 study of Ischemic Stroke, sponsored by Acorda Therapeutics.

Completed
Registry status
Phase 2
Development phase
83
Enrollment target
20
Study locations

NCT01605825 is a Phase 2 study of Ischemic Stroke that has completed, run by Acorda Therapeutics. The registered enrollment target is 83 participants, below the 1,462-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01605825, a Phase 2 study of Ischemic Stroke, has completed, sponsored by Acorda Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
83 participants
Enrollment target
20
Study locations

Study Summary

This is a multi-center, safety and tolerability study in subjects with chronic stable sensorimotor deficits after ischemic stroke. It has been designed as a double-blind, placebo-controlled, 2-period crossover study.

Conditions Studied

Ischemic Stroke

Interventions

  • DRUG placebo/dalfampridine-ER
  • DRUG dalfampridine-ER/placebo

Study Locations (20)

New York

  • Acorda Site #019 - Buffalo
  • Acorda Site #007 - West Haverstraw
  • Acorda Site #004 - White Plains

California

  • Acorda Site #018 - La Jolla
  • Acorda Site #016 - Newport Beach

Florida

  • Acorda Site #002 - Atlantis
  • Acorda Site #015 - Fort Lauderdale

Alabama

  • Acorda Site #011 - Birmingham

Connecticut

  • Acorda Site #006 - Fairfield

Georgia

  • Acorda Site #003 - Decatur

Kentucky

  • Acorda Site #021 - Lexington

Massachusetts

  • Acorda Site #009 - Boston

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2012-05
Est. Completion 2013-03
Phase Phase 2

Sponsor

Acorda Therapeutics

36 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01605825

The ClinicalTrials.gov registry entry for NCT01605825 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,462-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (94% lower). The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions - of which placebo/dalfampridine-ER is the first listed.

NCT01605825 reports 20 study locations spanning 16 distinct geographic areas - top geographies include New York, California, Florida.

Frequently Asked Questions

What is clinical trial NCT01605825 about?

NCT01605825 is a clinical study titled "A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke". This is a multi-center, safety and tolerability study in subjects with chronic stable sensorimotor deficits after ischemic stroke. It has been designed as a double-blind, placebo-controlled, 2-period crossover study.

What is the current status of trial NCT01605825?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2012-05. Estimated completion is 2013-03.

What conditions does trial NCT01605825 study?

This clinical trial studies the following conditions: Ischemic Stroke.

What interventions are being tested in trial NCT01605825?

The interventions under investigation include: placebo/dalfampridine-ER (DRUG), dalfampridine-ER/placebo (DRUG).

Who is sponsoring clinical trial NCT01605825?

This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01605825 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ischemic Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ischemic Stroke

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.